ClinicalTrials.gg
RecruitingNCT06776159LMWHUpdated Sep 18, 2026

The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD

An interventional study of Active Control and Standardized injection protocol in CVD - Cardiovascular Disease, Bruise and Pain, sponsored by The Hong Kong Polytechnic University. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Improper subcutaneous administration of LMWH may cause complications at the injection site. Standardized protocol for subcutaneous LMWH injections in patient with cardiovascular diseases is warranted to ensure consistent best practices in clinical settings.

Read the detailed description

This study examines the effect of standardized protocol in reducing complications for patients with cardiovascular disease.

02

Conditions studied

  • CVD - Cardiovascular Disease
  • Bruise
  • Pain

Keywords

  • LMWH injection
03

In context

Cardiovascular Diseases

5,368 studies on the registry are indexed under Cardiovascular Diseases; 939 are open to participants now.

This study's planned enrollment of 180 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 679 studies on the registry; 257 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who are in cardiac care units suffering from cardiovascular diseases prescribed with LMWH injections two times per day
  • Chinese

Exclusion criteria

Exclusion Criteria:

  • cognitively impaired
  • unconscious
  • refuse to participate
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Active Control

    The control group participants will receive the usual practice of subcutaneous LMWH injection administered by nurses.

    Other: Active Control

  • Experimental
    Standardized injection protocol

    The intervention group participants will receive standardized LMWH injection administered by nurses.

    Other: Standardized injection protocol

Interventions

  • OtherActive Control

    Patients in the control group will receive the usual practice of subcutaneous LMWH injection administered by nurses.

  • OtherStandardized injection protocol

    Nurses administer LMWH according to the standardized evidence-based protocol.

06

What researchers measure

Primary outcomes

  1. Bruise size

    The bruising length and width will be measured by a ruler and the incidence of bruising will be recorded.

    Time frame: 24 hours, 48 hours, 72 hours

  2. Pain level

    Patients' pain levels are assessed using the Numeric Rating Scale: from o to 10, with "10" representatin the worst outcome and with '0' representing the best outcome.

    Time frame: Immediately after injection, 24 hours, 48 hours, 72 hours

Secondary outcomes

  1. Patient Experience

    a Patient Experience Surveys to evaluate their perceived nurse's attitude

    Time frame: Immediately after receiving the injection

  2. Communicative Competence

    Communicative Competence Scale consists of 36 items across five dimensions (General Competence, Empathy Affiliation/Support, Behavioural Flexibility, and Social Relaxation), using a 5-point Likert scales ranging from strongly agree to strongly disagree (coded from 1 to 5). Higher the score means worse the outcome.

    Time frame: Immediately before and after injection

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06776159
Responsible party
CHEUNG Pui Yu Frankie (Assistant Professor of Practice, The Hong Kong Polytechnic University) — Principal investigator
First posted
Jan 15, 2025
Start date
Jun 24, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Frankie CHEUNG
Contact
frankie.py.cheung@polyu.edu.hk
852 2766 7991
Arkers Wong
Contact
arkers.wong@polyu.edu.hk
852 3400 3805
Arkers Wong
principal investigator · The Hong Kong Polytechnic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion